Last reviewed · How we verify
Losmapimod for single dose
At a glance
| Generic name | Losmapimod for single dose |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Evaluation of Safety, Tolerability, and Changes in Biomarker and Clinical Outcome Assessments of Losmapimod for FSHD1 With Extension (PHASE2)
- Relative Bioavailability and Food Effect Study of Losmapimod 15 mg Tablets (PHASE1)
- Phase I Study of GW856553 (Losmapimod) (PHASE1)
- A Study to Evaluate the Effect of Losmapimod on Cardiac Conduction as Compared to Placebo and Moxifloxacin (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Losmapimod for single dose CI brief — competitive landscape report
- Losmapimod for single dose updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI